ESSA Pharma (EPIX) Stock Price
ESSA Pharma Price
Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus.
ESSA Pharma stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of ESSA Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ESSA Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ESSA Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | ESSA Pharma Price |
|---|
ESSA Pharma Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
ESSA Pharma Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | 22.00 | 177.00 | – | 495.00 | 647.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | 704.55 | – | – | 30.71 |
| -15.00 | -18.00 | -16.00 | -11.00 | -12.00 | -23.00 | -37.00 | -36.00 | -32.00 | -34.00 | -33.00 | -22.00 | -22.00 | -23.00 | 431.00 | – |
| – | – | – | – | – | – | – | – | – | – | – | -100.00 | -12.43 | – | 87.07 | – |
| -9.00 | -13.00 | -4.00 | -11.00 | -12.00 | -23.00 | -36.00 | -35.00 | -26.00 | -28.00 | -32.00 | -8.00 | -22.00 | -22.00 | 380.00 | 488.00 |
| 800.00 | 44.44 | -69.23 | 175.00 | 9.09 | 91.67 | 56.52 | -2.78 | -25.71 | 7.69 | 14.29 | -75.00 | 175.00 | – | -1,827.27 | 28.42 |
| 0.92 | 1.35 | 1.45 | 4.57 | 8.43 | 22.44 | 38.48 | 44.04 | 44.09 | 44.28 | 44.28 | 44.28 | 44.28 | 44.28 | 44.28 | 44.28 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales ESSA Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ESSA Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ESSA Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares ESSA Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ESSA Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
ESSA Pharma stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
ESSA Pharma Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
ESSA Pharma business model & stock analysis
ESSA Pharma SWOT Analysis
Strengths
1. Strong pipeline of innovative pharmaceutical products.
2. Cutting-edge research and development capabilities.
3. High level of expertise in targeted cancer therapeutics.
Weaknesses
1. Relatively small scale of operations compared to larger pharmaceutical companies.
2. Limited financial resources for large-scale clinical trials.
3. Dependence on a small number of key personnel for research and development.
Opportunities
1. Growing demand for targeted cancer therapies in the global market.
2. Potential partnerships and collaborations with larger pharmaceutical companies.
3. Expansion into new geographic markets with unmet medical needs.
Threats
1. Intense competition from well-established pharmaceutical companies.
2. Stringent regulatory requirements and approval processes.
3. Rapidly evolving landscape of cancer treatment technologies.
ESSA Pharma Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
ESSA Pharma historical P/E ratio, EBIT multiple, and P/S ratio
ESSA Pharma annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
ESSA Pharma shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
ESSA Pharma stock splits
ESSA Pharma Dividend History
1 years of dividend payments
ESSA Pharma dividend history and estimates
Max
Details
Current ESSA Pharma forecasts and price targets in August 2026
Analyst Price Targets 2026ESSA Pharma Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/11/2026 | -0.04USD | - | 0.00USD | - | 2026 Q3 |
| 5/6/2026 | -0.04USD | - | 0.00USD | - | 2026 Q2 |
| 2/9/2026 | -0.04USD | - | 0.00USD | - | 2026 Q1 |
| 12/15/2025 | -0.16USD | - | -USD | - | 2025 Q4 |
| 12/10/2024 | -0.20USD | - | 0.00USD | - | 2024 Q4 |
| 5/7/2024 | -0.28USD | - | 0.00USD | - | 2024 Q2 |
| 2/5/2024 | -0.24USD | - | 0.00USD | - | 2024 Q1 |
| 12/11/2023 | -0.29USD | - | 0.00USD | - | 2023 Q4 |
| 8/2/2023 | -0.34USD | - | 0.00USD | - | 2023 Q3 |
| 5/8/2023 | -0.35USD | - | 0.00USD | - | 2023 Q2 |
ESSA Pharma shareholder structure
| % | Name |
|---|---|
106.84619% | |
0.17399% | |
0.00836% | |
0.00000% | |
0.00000% | |
0.00000% |
ESSA Pharma Executives and Management Board
4 members · avg. age 64 · 25 % women
Dr. Alessandra Cesano (65)
Executive Vice President, Chief Medical Officer
2.49 M USD
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Mr. David Wood (63)
Chief Financial Officer
Mr. Jon Adkins
President, Treasurer, Secretary, Director · since 2025
ESSA Pharma Supply Chain
ESSA Pharma Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.59 | -0.05 | -0.06 | ||
| 2 | -0.80 | -0.20 | -0.03 | ||
| 3 | -0.65 | -0.37 | 0.20 |
Frequently asked questions about ESSA Pharma
The business model of ESSA Pharma Inc revolves around the development and commercialization of novel therapies for the treatment of prostate cancer. As a pharmaceutical company, ESSA Pharma Inc focuses on advancing innovative drugs that target the N-terminal domain of the androgen receptor, a key driver of prostate cancer growth. By leveraging its expertise in drug discovery and clinical development, the company aims to provide effective treatment options for patients suffering from advanced prostate cancer. With a strong emphasis on research and development, ESSA Pharma Inc strives to bring transformative therapies to market, ultimately improving the lives of prostate cancer patients.
ESSA Pharma Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of ESSA Pharma Inc in the market include leading biotechnology companies such as Genentech, Pfizer, Novartis, and Johnson & Johnson. These companies, like ESSA Pharma Inc, are actively involved in the development and commercialization of innovative pharmaceutical products, including therapeutics for oncology and other diseases. In this competitive landscape, ESSA Pharma Inc aims to differentiate itself by focusing on its unique approach to drug discovery and developing cutting-edge therapies that target therapeutically relevant proteins in cancer.
ESSA Pharma Inc. is a biopharmaceutical company specializing in the development of novel medicines for the treatment of prostate cancer. Founded in 2009, ESSA Pharma has made remarkable strides in advancing targeted therapies to improve patients' outcomes. The company focuses on developing drugs that inhibit the N-terminal domain of the androgen receptor, which plays a vital role in the growth and progression of prostate cancer. With a dedicated team of experienced researchers and a robust pipeline, ESSA Pharma Inc. aims to revolutionize prostate cancer treatment by providing innovative and effective therapies to patients worldwide.
ESSA Pharma Inc, a leading pharmaceutical company, has successfully achieved multiple significant milestones. The company made remarkable progress in the development of their product portfolio. Notably, ESSA Pharma Inc received regulatory approvals for several clinical trials, demonstrating their commitment to advancing novel therapies. They also secured strategic partnerships and collaborations with renowned industry players, enabling them to drive further innovation and expand their reach. ESSA Pharma Inc's dedication to researching and developing innovative solutions has positioned them as a key player in the pharmaceutical sector. By focusing on groundbreaking initiatives, they continue to make substantial strides in improving patient outcomes and advancing the field of medicine.
ESSA Pharma Inc is primarily present in the United States and Canada.
ESSA Pharma Inc represents a values-driven and progressive corporate philosophy. With a focus on innovation, integrity, and collaboration, the company strives to advance novel therapies for the treatment of advanced prostate cancer and other hormonally-driven diseases. ESSA Pharma Inc is committed to delivering breakthrough solutions that improve patient outcomes and quality of life. With a dedicated team of experts and a culture of scientific excellence, ESSA Pharma Inc is driven by a strong commitment to addressing unmet medical needs and revolutionizing the field of oncology.
7 analysts currently rate the ESSA Pharma stock: 0 recommend buying, 4 holding and 3 selling. For 2026, analysts expect ESSA Pharma to generate revenue of 22.72 M USD and earnings per share of -0.18 USD.
The ESSA Pharma share (EPIX) is listed on 1 stock exchanges, including: NASDAQ (EPIX).
ESSA Pharma Inc. is a Canadian biopharmaceutical company specializing in the development of innovative therapies for the treatment of cancer. The company focuses on the discovery and development of drugs targeting the androgen receptor (AR) signaling pathway, an important mechanism that contributes to tumor progression in many forms of cancer. The business model of ESSA Pharma Inc. is based on the identification, development, and commercialization of drugs targeting the androgen receptor (AR). The company has focused on the production of new compounds that can inhibit activated androgen receptors. By blocking this protein on the surface of cancer cells, the spread of tumors is expected to be reduced. ESSA Pharma Inc. focuses on the development of pharmaceutical products, with an emphasis on research and development of small molecules that can inhibit the androgen receptor signaling pathway. ESSA is currently in the clinical phase of developing a promising drug called EPI-506. Using an in vitro platform, the company has developed several other molecules that have the potential to be tested in additional clinical trials. The core of ESSA Pharma's business model is the research, development, and commercialization of therapies for the treatment of specific types of cancer, with a focus on prostate cancer. ESSA collaborates closely with experts and researchers in the field of oncology and clinical research to develop the most effective therapies. The company also offers services in the area of clinical trial organization, including support for phase I-II testing, phase III clinical trials, and market strategies. ESSA's services also include the management and operation of clinical trials on behalf of third-party companies. ESSA Pharma's business model is designed for long-term success. By identifying and focusing on a specific target group of cancer patients and collaborating with experienced researchers in the field of oncology and clinical research, the company positions itself as a pioneer and innovator in cancer research. Investments in the research and development of new therapies, as well as the incorporation of expertise in clinical trials and strategies, promote the growth and success of ESSA. Cancer is one of the greatest medical challenges worldwide, and there is a high demand for effective therapies. ESSA Pharma Inc. positions itself as an innovative biopharmaceutical company that is a leader in the treatment of cancer through its research and development of therapies targeting the androgen receptor signaling pathway. With its close collaboration with leading experts in oncology and clinical research, the company is well-positioned to achieve long-term success.
The expected revenue of ESSA Pharma is 22.72 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of ESSA Pharma is -8.13 M USD. The net profit reflects the company's profitability after deducting all expenses.
The P/E ratio cannot be calculated for ESSA Pharma at the moment.
The P/S cannot be calculated for ESSA Pharma currently.
The Eulerpool Quality Score for ESSA Pharma is 2/10.
The ISIN of ESSA Pharma is CA29668H7085. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of ESSA Pharma is A2JKQ4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of ESSA Pharma is EPIX. The ticker symbol is used to trade ESSA Pharma shares on the stock exchange.
ESSA Pharma is assigned to the 'Health' sector.
The dividends of ESSA Pharma are distributed in USD.
ESSA Pharma stock
ESSA Pharma Peer Group
ESSA Pharma Ticker
ESSA Pharma FIGI
All fundamentals and in-depth analysis of ESSA Pharma
Our stock analysis for ESSA Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ESSA Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.